Stem Cell
Treating Disease with Stem Cells This article was written by Dr. Gregory Hale, professor of Pediatrics at the University of Kentucky College of Medicine, in response to questions posed by Scientific American Magazine regarding the treatment of certain diseases with cord blood stem cells. There is some additional information provided by Viacord, a medical service company that provides private family cord blood banking, processing, and research. Dr. Hale discussed the advantages of cord blood stem cell transplants, the results of several transplants, as well as the research that on-going in the field of stem cell transplantation. The blood that remains in the human umbilical cord blood following birth contains a rich source of hematopoietic progenitor cells known as “stem cells.” These stem cells are the master cells of the blood. They divide to make new red cells that supply oxygen, white blood cells that fight disease and infection, and platelets that facilitate healing. Doctors now have three sources of stem cells available to them: bone marrow, mobilized bone marrow or peripheral blood, and umbilical cord blood. Bone marrow has traditionally been used as a source of stem cells, but research is proving that cord blood may be
an excellent alternative source. Cord blood can be utilized for the treatment of many diseases, including leukemia, sickle cell anemia, and Hodgkin’s disease. The first successful cord blood transplant took place in 1988 when a newborn’s cord blood was used in a life saving stem cell transplant for her older brother who had Fanconi anemia. Since then, there has been much research into the advantages of cord blood stem cells. Cord blood is much more readily available and poses no donor risk. The blood is simply collected from the placenta and umbilical cord after the baby is born and stored. The potential of expanding the ethnic diversity of the donor pool is greatly increased, since minorities are considerably under-represented in bone marrow transplant pools. Cord blood stem cells may also pose less risk of graft-versus-host disorder, or GVHD, than stem cells from bone marrow. GVHD occurs when the donor’s immune cells make antibodies against the host’s tissues, resulting in serious complications. In the last ten years, several studies of cord blood transplants have taken place and their results have been published in science and medical journals. In 1996, the New England Journal of Medicine reported the results of 25 consecutive cord blood transplantations from August 1993 to November 1995 by Dr. Joanne Kurtzberg at Duke University. After bone marrow searches were unsuccessful for 17 patients, cord blood was collected from unrelated donors at the New York Blood Center. Nineteen patients had malignant diseases and four had nonmalignant conditions. The pati
Some topics in this essay:
Dr Hale,
Epstein Barr,
Minnesota Hospital,
Leukocyte Antigen,
Nonmalignant Diseases,
California Fortunately,
cord blood,
American Magazine,
Center Nineteen,
Lymphoblastic Leukemia,
Journal Medicine,
stem cells,
bone marrow,
syndrome ·,
cord blood stem,
blood stem,
graft-versus-host disease,
blood stem cells,
cord blood transplants,
umbilical cord,
stem cell,
blood transplants,
patients malignant,
source stem cells,
severe graft-versus-host disease,
Join now to see the rest of the essay!
Approximate Word count = 1060
Approximate Pages = 4 (250 words per page double spaced)
More Essays on Stem Cell
Professional Papers: |
CUSTOMER SERVICES
|
|
Saved Papers
You haven't saved any papers.
|
Example Essays Home
